Omada Health CFO Steven Cook disposes of $325,394 in company stock

Omada Health (OMDA) reported Q1 2026 results with EPS of -$0.05 vs -$0.08 forecast and revenue of $78M (+42% YoY), alongside a Citizens price-target raise to $21 from $18 (Market Outperform). CFO Steven L. Cook sold 17,950 shares for $325,394 at a weighted avg of $18.1278 under a 10b5-1 plan, while also exercising options to buy the same number of shares for $140,112 (prices $7.68–$8.01), as an amended Form 4 corrected omission of these exercises. The stock has since climbed to $22.98, up 49% over 6 months and 46% YTD, though it is flagged as trading above InvestingPro fair value.

Analysis

This filing is low-signal on ownership intent because the sale was pre-programmed and mechanically paired with an option exercise. The real market issue is valuation: OMDA is being asked to justify a software-like multiple while still proving that growth can convert into durable free cash flow. That setup is fragile because any deceleration in member adds, retention, or margin expansion will hit the multiple before it hits the income statement.

Near term, the stock is more sensitive to the next guide than to the insider print. If revenue growth stays in the high-30s or better and losses narrow again, insider monetization should be absorbed as routine liquidity management. If growth slips toward the low-30s, the downside is mostly multiple compression, not an earnings miss; that would also pressure adjacent digital-health names as investors reprice the category away from 'fast growth' and toward 'prove-it' economics.

Contrarian view: the crowd may be over-reading the optics while underweighting the fact that management is still retaining a meaningful equity stake. The bigger question is whether OMDA can sustain its current premium once the market stops rewarding narrative and starts discounting execution risk. Falsifier: another quarter of >35% growth with improving contribution margin and cash burn would keep the premium intact; any guidance cut, slower new business momentum, or weaker profitability path would likely trigger a sharp derating.

Key Decisions for Investors

• Do not short OMDA purely on the Form 4; treat the insider activity as noise unless the next earnings update weakens the growth/profitability path.
• If already long OMDA, use strength to sell 1-2 month covered calls 10-15% above spot; the upside is increasingly dependent on flawless execution, so monetizing premium is attractive.
• Relative-value trade: long OMDA / short TDOC over the next 1-3 months. OMDA has the cleaner path to operating leverage, while TDOC is the better hedge against sector multiple compression if digital-health sentiment fades.
• Alert level: if OMDA trades below its next-earnings post-gap support or management guides revenue growth below the mid-30s, consider a 3-6 month put spread targeting a 15-20% re-rating lower.